PROQR THERAPEUTICS EO-04 (0PQ) — Cash Flow Reinvestment Rate

Latest as of December 2023: 0.06x

PROQR THERAPEUTICS EO-04 (0PQ) has a Cash Flow Reinvestment Rate of 0.06x as of December 2023, reinvesting €1.37 Million (capex €1.37 Million ) from operating cash flow of €21.55 Million. See cash generation quality of PROQR THERAPEUTICS EO-04 to measure how efficiently the company converts operating cash flow to free cash.

Reinvestment Rate

0.06x

(Capex + Investments) / Operating CF

Total Reinvested

€1.37 Million

Capex + Investments

Operating Cash Flow

€21.55 Million

EUR

Capital Expenditures

€1.37 Million

EUR

PROQR THERAPEUTICS EO-04 Cash Flow Reinvestment Rate (2023–2023)

Historical reinvestment intensity for PROQR THERAPEUTICS EO-04 across 1 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of PROQR THERAPEUTICS EO-04.

Annual Cash Flow Reinvestment Rate for PROQR THERAPEUTICS EO-04 (2023–2023)

Year-by-year capital reinvestment analysis for PROQR THERAPEUTICS EO-04. See 0PQ free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.

Year	Reinvestment Rate	Total Reinvested (EUR)	Operating CF	Capex	YoY Change
2023	0.06x	€1.37 Million	€21.55 Million	€1.37 Million	—

Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow